INFO & CONTACTS:  +39 02 2390 1

A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First-Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN)

Phase: Phase II-III clinical trials

Principal Investigator: Professoressa Associata Licitra Lisa Francesca Linda

Main Facility: Oncologia Medica 3 - Tumori testa-collo

Drug: INBRX-106
Pembrolizumab

Pathologies: Other

ClinicalTrials.gov: Read the details about clinical trials

HexAgon-HN study is a clinical trial evaluating the activity of  INBRX-106 in combination with pembrolizumab chemotherapy in patients with locally recurrent and/or distant metastatic squamous cell carcinoma of the head and neck, who have not yet received treatment for recurrent disease with CPS≥20. 

INBRX-106 is a recombinant, humanized, hexavalent IgG1 agonist antibody that specifically recognizes and stimulates OX40, also known as tumor necrosis factor receptor superfamily member 4 (TNFRSF4) or CD134, an important costimulator of T-cell responses.  

 Pembrolizumanb is a drug known as inhibitor designed to act by targeting specific parts of immune cells. Specifically, Pembrolizumab acts on a protein called Programmed cell Death Protein 1 (PD-1), which is located on the surface of immune cells and prevents the immune system from attacking cancer cells. By targeting these proteins, INBRX-106 e pembrolizumab help the immune system improve its ability to attack and destroy cancer cells.  

This study, conducted in accordance with international ethical guidelines, is considered experimental, as INBRX-106 has not been approved by health authorities for the treatment of head and neck cancer. By contrast, the potential impact of Pembrolizumab has already been demonstrated in previous clinical studies, supporting the biological and clinical rationale that immune checkpoint inhibitors may improve prognosis in this patient population. 

The objective of this study is therefore to achieve greater oncological responses to the experimental drug INBRX-106 in combination with Pembrolizumab, and to improve progression-free survival in these patients. 

 

This is an open-label, randomized study. 

The term "open-label" means that the patient, the doctor, and the study staff all know which study drugs are being administered. 

  • The term "randomized" means that the study drugs are assigned randomly, like flipping a coin. Assignment to one treatment group or the other will occur through a computerized system called "randomization", which randomly allocates patients to treatment groups, without any decision-making by the investigator or the patient. There will be a 50% chance of being assigned to Group A and a 50% chance of being assigned to Group B:  
  • Group A: will receive INBRX-106 and pembrolizumab  
  • Group B: will receive pembrolizumab 

The feasibility of enrollment in the study depends on patient characteristics (demographics, oncological history, and comorbidities), laboratory tests, and radiological parameters, which will be assessed through specific screening examinations before starting treatment. These assessments will be performed at this institution according to well-defined timelines. 

The treatment schedule will be as follows: 

  • Pembrolizumab, with or without INBRX-106 administered via intravenous infusion every 3 weeks, for up to 35 cycles (approximately 2 years) 

Treatment will continue until maximum response is achieved and in accordance with the study protocol. Treatment will be discontinued in case of disease progression, unacceptable toxicity, or, as always in clinical trials, if decided by either the investigator or the patient (who will nonetheless continue to have access to medical care and will not forfeit any legal rights or benefits to which they are entitled). 

Patients will also be monitored for adverse events caused by chemotherapy and for immune-related toxicities induced by immunotherapy, as a result of immune system overactivity. In fact, it can happen that immunotherapy treatment causes adverse events—many of which are already known—because the immune system may attack not only diseased cells but also healthy ones, being no longer able to recognize them. In such cases, the investigators will propose symptomatic therapies and implement targeted strategies to reduce the intensity of these side effects (e.g., therapeutic pauses, dose reductions, corticosteroid-based treatments, etc.). To ensure patient safety from the toxicities of chemotherapy and immunotherapy, study participants will be closely monitored. 

The study team remains available for more detailed information (email: amo@istitutotumori.mi.it). 

Last update: 12/05/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe